Sorafenib S.K. is indicated for the treatment of patients with advanced renal cell carcinoma. Treatment of patients with hepatocellular carcinoma. Sorafenib S.K. is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
